Oxandrolone can cause serious hepatic injury (including liver tumors or peliosis hepatis) and adverse lipid changes that raise cardiovascular risk; seek medical attention for jaundice, severe abdominal pain, chest pain, or shortness of breath. In June 2023 the FDA withdrew approval for all commercially manufactured oxandrolone tablets (Oxandrin® and generics)
